title: Genetic engineering strategies to prevent the effects of antibody and complement on xenogeneic chondrocytes.
abstract: Advances in animal transgenesis may allow using xenogeneic chondrocytes in tissue-engineering applications for clinical cartilage repair. Porcine cartilage is rejected by humoral and cellular mechanisms that could be overcome by identifying key molecules triggering rejection and developing effective genetic-engineering strategies. Accordingly, high expression of α1,2-fucosyltransferase (HT) in xenogeneic cartilage protects from galactose α1,3-galactose (Gal)-mediated antibody responses. Now, we studied whether expression of a complement inhibitor provides further protection. First, porcine articular chondrocytes (PAC) were isolated from non-transgenic, single and double transgenic pigs expressing HT and moderate levels of human CD59 (hCD59) and their response to human serum was assessed. High recombinant expression of human complement regulatory molecules hCD59 and hDAF was also attained by retroviral transduction of PAC for further analyses. Complement activation on PAC after exposure to 20 % human serum for 24 hours mainly triggered the release of pro-inflammatory cytokines IL-6 and IL-8. Transgenic expression of HT and hCD59 did not suffice to fully counteract this effect. Nevertheless, the combination of blocking anti-Gal antibodies (or C5a) and high hCD59 levels conferred very high protection. On the contrary, high hDAF expression attained the most dramatic reduction in IL-6/IL-8 secretion by a single strategy, but the additional inhibition of anti-Gal antibodies or C5a did not provide further improvement. Notably, we demonstrate that both hCD59 and hDAF inhibit anaphylatoxin release in this setting. In conclusion, our study identifies genetic-engineering approaches to prevent humoral rejection of xenogeneic chondrocytes for use in cartilage repair.
authors.affiliation: IDIBELL, Hospital Duran i Reynals, Gran Via de L'Hospitalet 199, 08908 L'Hospitalet de Llobregat, Barcelona, SPAIN.ccosta@idibell.cat.
authors.forename: R
authors.initials: R
authors.lastname: Sommaggio
authors.forename: D
authors.initials: D
authors.lastname: Bello-Gil
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Cruz
authors.forename: J L
authors.initials: JL
authors.lastname: Brokaw
authors.forename: R
authors.initials: R
authors.lastname: Máñez
authors.forename: C
authors.initials: C
authors.lastname: Costa
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D000906:Antibodies / Q000276:immunology*; D002356:Cartilage / Q000166:cytology*; D019902:Chondrocytes / Q000166:cytology*; D003165:Complement System Proteins / Q000009:adverse effects*; D004195:Disease Models, Animal; D005818:Genetic Engineering; D013552:Swine; D014183:Transplantation, Heterologous / Q000379:methods
chemical_list: D000906:Antibodies; D003165:Complement System Proteins